TScan Therapeutics (TCRX) announced a major strategic realignment prioritizing its lead hematologic program, TSC-101, while pausing enrollment in the solid tumor Phase 1 trial.
Pipeline & Clinical Milestones: The company reached agreement with the FDA on the pivotal trial design for TSC-101 targeting AML/MDS patients, utilizing a biologically assigned control arm with Relapse-Free Survival (RFS) as the primary endpoint. The pivotal trial is scheduled to launch in Q2 2026. Manufacturing improvements have been implemented for TSC-101, aiming for a commercial-ready process that reduces cycle
...